100 related articles for article (PubMed ID: 2284219)
1. Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation.
Warrington SJ; Lewis Y; Dawnay A; Johnston A; Kovacs IB; Lamb E; Ravic M
Postgrad Med J; 1990; 66 Suppl 4():S35-40. PubMed ID: 2284219
[TBL] [Abstract][Full Text] [Related]
2. Piroxicam-beta-cyclodextrin: effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men.
Warrington S; Debbas N; Farthing M; Horton M; Umile A
Int J Tissue React; 1991; 13(5):243-8. PubMed ID: 1806546
[TBL] [Abstract][Full Text] [Related]
3. Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men.
Warrington SJ; Debbas NM; Farthing M; Horton M; Johnston A; Thillainayagam A; Turner P; Ferber H
Postgrad Med J; 1990 Aug; 66(778):622-6. PubMed ID: 2217030
[TBL] [Abstract][Full Text] [Related]
4. Effects of piroxicam-beta-cyclodextrin on the gastrointestinal tract.
Warrington S
Eur J Rheumatol Inflamm; 1993; 12(4):29-37. PubMed ID: 7805701
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis.
Kidd B; Frenzel W
J Rheumatol; 1996 Sep; 23(9):1605-11. PubMed ID: 8877932
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
7. The protective effect of nitroglycerin on gastrointestinal and renal side effects of lornoxicam in rats.
Sen S; Doger FK; Sen S; Aydin ON; Karul A; Dost T
Eur J Pharmacol; 2006 Jul; 541(3):191-7. PubMed ID: 16765342
[TBL] [Abstract][Full Text] [Related]
8. Lornoxicam efficacy in acute pain (LEAP) trial.
Sharma A; Pingle A; Baliga VP
J Indian Med Assoc; 2008 Dec; 106(12):811-3. PubMed ID: 19370957
[TBL] [Abstract][Full Text] [Related]
9. Patient-controlled analgesia with lornoxicam vs. dipyrone for acute postoperative pain relief after septorhinoplasty: a prospective, randomized, double-blind, placebo-controlled study.
Sener M; Yilmazer C; Yilmaz I; Caliskan E; Donmez A; Arslan G
Eur J Anaesthesiol; 2008 Mar; 25(3):177-82. PubMed ID: 17953792
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
13. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lornoxicam for acute postoperative pain relief after septoplasty: a comparison with diclofenac, ketoprofen, and dipyrone.
Sener M; Yilmazer C; Yilmaz I; Bozdogan N; Ozer C; Donmez A; Arslan G
J Clin Anesth; 2008 Mar; 20(2):103-8. PubMed ID: 18410864
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lornoxicam in man.
Hitzenberger G; Radhofer-Welte S; Takacs F; Rosenow D
Postgrad Med J; 1990; 66 Suppl 4():S22-7. PubMed ID: 2284217
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
Ravic M; Johnston A; Turner P
Postgrad Med J; 1990; 66 Suppl 4():S30-4. PubMed ID: 2126624
[TBL] [Abstract][Full Text] [Related]
17. Influence of lornoxicam on serum pepsinogen levels.
Kullich W; Klein G; Pöllmann G
Postgrad Med J; 1990; 66 Suppl 4():S46-8. PubMed ID: 2149454
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study.
Sádaba B; Azanza JR; Quetglas EG; Campanero MA; Honorato J; Coronel P; Gimeno M
Rev Esp Quimioter; 2007 Mar; 20(1):51-60. PubMed ID: 17530036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
